ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full...(pGeneral and administrative 2951 ...)

Total cost and expenses 5,744 4,835 17,020 17,029

Operating loss (5,037) (2,185) (15,692) (8,669)

Interest and other

income, net 63 159 381 548

Interest expense (450) (187) (1,515) (862)

Gain on extinguishment

of debt 16,127 - 16,127 219

Net income (loss) 10,703 (2,213) (699) (8,764)

Deemed dividend from

beneficial conversion

feature for Series F

redeemable convertible

preferred stock - - - (13,842)

Accretion of dividends

on preferred stock (441) - (1,167) (867)

Reversal of accretion

of dividends on

preferred stock not paid - - - 4,919

Net loss attributed to

common stockholders $10,262 $(2,213) $(1,866) $(18,554)

Net loss per share:

- Basic and diluted $3.94 $(0.24) $(0.72) $(3.16)

Shares used in computing

net loss per share:

- Basic and diluted 2,606,739 9,070,994 2,599,425 5,868,131

ImaRx Therapeutics, Inc.

Selected Balance Sheet Data (in thousands)

December 31 December 31

2006 2007

ASSETS

Current assets:

Cash and cash equivalents $4,256 $12,861

Restricted cash - 388

Accounts receivable, net 576 349

Inventory
'/>"/>